Julie Park works with a variety of public and private company clients, including tech companies and startups.

Julie’s practice focuses on corporate matters and securities transactions, including initial public offerings, mergers and acquisitions, private placements, venture capital financings and other corporate and transactional matters. Julie has also represented clients in a number of SPAC transactions. Prior to joining Pillsbury, Julie practiced in New York, where she represented a broad range of financial institutions in acquisition financings, syndicated loan transactions, refinancings and secured and unsecured high-yield bond offerings.

Representative Experience

  • Represented Invitae Corporation in its acquisition of ArcherDX for $1.4 billion, as well as equity and debt offerings, including its $400 million ATM offering and its $1.15 billion investment in convertible senior notes.
  • Represented Nikola Corporation in its $275 million common stock and green convertible senior notes offering, $3.3 billion de-SPAC merger with VectoIQ Acquisition Corp., $525 million PIPE, and the listing of Nikola’s common stock on the Nasdaq Global Select Market, as well as its aggregate $600 million equity lines of credit.
  • Represented Quantum in its $67.5 million oversubscribed Rights Offering, a deal honored as the 2022 Best Governance Around a Corporate Transaction by Corporate Secretary.

View More

  • Represented TD SYNNEX Corporation in its $885 million secondary public offering in 2024, $87.3 million secondary public offering in 2023, acquisition of Convergys Corporation for $2.4 billion and its acquisition of Westcon-Comstor’s American operations from Datatec Ltd. for $800 million, a deal honored as the 2018 Global Corporate Deal of the Year (Mid-Market) by M&A Atlas Global Markets Awards.
  • Represented BioLegend in its $5.25 billion acquisition by PerkinElmer, Inc.
  • Represented Vincerx Pharma, Inc. in its $280 million de-SPAC business combination with LifeSci Acquisition Corp. and the listing of Vincerx’s common stock on the Nasdaq Capital Market, its $50.75 million PIPE and its $16.5 million public offering of common stock and warrants.
  • Represented Interactive Strength (FORME) in its $12 million IPO.
  • Represented SiTime Corporation in its $57 million IPO.
  • Represented the underwriters in Aquantia Corp.’s $61 million IPO.
  • Represented Salarius Pharmaceuticals in its merger with Flex Pharma Inc., and the listing of Salarius’ common stock on the Nasdaq Capital Market.
  • Represented Inphi Corporation in its $216 million acquisition of eSilicon Corporation.
  • Represented Identiv, Inc. in the $145 million sale of its physical security, access card and identity reader operations and assets to Vitaprotech Group SAS.
  • Represented YuMe Inc. in its sale to RhythmOne plc for $185 million, a deal honored as the 2019 Cross-Border M&A Deal of the Year (Mid-Market) by M&A Atlas Global Markets Awards and as the Corporate/Strategic Deal of the Year ($100M – $250M) by M&A Advisor.

Professional Highlights

  • Speaker, “Startup Environment,” 82-BioX Healthcare Summit, June 1, 2024
  • Speaker, “Going Public: Preparing for an IPO in the U.S.: Key Considerations and Challenges in a Changing World,” ABA Asia/Pacific Conference: Law and Technology in a Changing World, October 11, 2023


  • J.D., Georgetown University Law Center, 2011

    B.A., Korea University, 2006


  • California

    New York


  • Chinese (Mandarin)